Literature DB >> 15516845

A636P testing in Ashkenazi Jews.

Jose G Guillem1, Harvey G Moore, Crystal Palmer, Emily Glogowski, Rob Finch, Khedoudja Nafa, Arnold J Markowitz, Kenneth Offit, Nathan A Ellis.   

Abstract

Hereditary nonpolyposis colorectal cancer (HNPCC) is an autosomal dominantly inherited colorectal cancer syndrome attributable to mutations in one of several DNA mismatch repair genes, most commonly MLH1 and MSH2 . In certain populations, founder mutations account for a substantial portion of HNPCC. In this report we summarize the literature and our personal experience testing for a specific founder mutation in the Ashkenazi Jewish population, MSH2*1906G > C , also known as A636P. Although rare in the general population, the A636P mutation is detected in up to 7% of Ashkenazi Jewish patients with early age-of-onset colorectal cancer, and may account for up to one third of HNPCC in the Ashkenazi Jewish population. In addition, we summarize our initial experience with a prospective A636P testing protocol aimed at Ashkenazi Jewish patients at high or intermediate risk for harboring the A636P mutation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15516845     DOI: 10.1007/s10689-004-0899-z

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  24 in total

1.  Age and origin of two common MLH1 mutations predisposing to hereditary colon cancer.

Authors:  A L Moisio; P Sistonen; J Weissenbach; A de la Chapelle; P Peltomäki
Journal:  Am J Hum Genet       Date:  1996-12       Impact factor: 11.025

2.  Germ-line mutation of the hMSH6/GTBP gene in an atypical hereditary nonpolyposis colorectal cancer kindred.

Authors:  Y Akiyama; H Sato; T Yamada; H Nagasaki; A Tsuchiya; R Abe; Y Yuasa
Journal:  Cancer Res       Date:  1997-09-15       Impact factor: 12.701

3.  Phenotypic analysis of hMSH2 mutations in mouse cells carrying human chromosomes.

Authors:  G Marra; S D'Atri; H Yan; C Perrera; E Cannavo'; B Vogelstein; J Jiricny
Journal:  Cancer Res       Date:  2001-11-01       Impact factor: 12.701

4.  Recurrent germline mutation in MSH2 arises frequently de novo.

Authors:  D C Desai; J C Lockman; R B Chadwick; X Gao; A Percesepe; D G Evans; M Miyaki; S T Yuen; P Radice; E R Maher; F A Wright; A de La Chapelle
Journal:  J Med Genet       Date:  2000-09       Impact factor: 6.318

5.  Hereditary susceptibility to colorectal cancer. Relatives of early onset cases are particularly at risk.

Authors:  N R Hall; D T Bishop; B M Stephenson; P J Finan
Journal:  Dis Colon Rectum       Date:  1996-07       Impact factor: 4.585

6.  The founder mutation MSH2*1906G-->C is an important cause of hereditary nonpolyposis colorectal cancer in the Ashkenazi Jewish population.

Authors:  W D Foulkes; I Thiffault; S B Gruber; M Horwitz; N Hamel; C Lee; J Shia; A Markowitz; A Figer; E Friedman; D Farber; C M T Greenwood; J D Bonner; K Nafa; T Walsh; V Marcus; L Tomsho; J Gebert; F A Macrae; C L Gaff; B Bressac-De Paillerets; P K Gregersen; J N Weitzel; P H Gordon; E MacNamara; M-C King; H Hampel; A De La Chapelle; J Boyd; K Offit; G Rennert; G Chong; N A Ellis
Journal:  Am J Hum Genet       Date:  2002-11-26       Impact factor: 11.025

7.  Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC.

Authors:  S J Laken; G M Petersen; S B Gruber; C Oddoux; H Ostrer; F M Giardiello; S R Hamilton; H Hampel; A Markowitz; D Klimstra; S Jhanwar; S Winawer; K Offit; M C Luce; K W Kinzler; B Vogelstein
Journal:  Nat Genet       Date:  1997-09       Impact factor: 38.330

8.  A636P is associated with early-onset colon cancer in Ashkenazi Jews.

Authors:  José G Guillem; Beth S Rapaport; Tomas Kirchhoff; Prema Kolachana; Khedoudja Nafa; Emily Glogowski; Rob Finch; Helen Huang; William D Foulkes; Arnold Markowitz; Nathan A Ellis; Kenneth Offit
Journal:  J Am Coll Surg       Date:  2003-02       Impact factor: 6.113

9.  Genetic instability occurs in the majority of young patients with colorectal cancer.

Authors:  B Liu; S M Farrington; G M Petersen; S R Hamilton; R Parsons; N Papadopoulos; T Fujiwara; J Jen; K W Kinzler; A H Wyllie; B Vogelstein; M G Dunlop
Journal:  Nat Med       Date:  1995-04       Impact factor: 53.440

10.  MSH2 c.1452-1455delAATG is a founder mutation and an important cause of hereditary nonpolyposis colorectal cancer in the southern Chinese population.

Authors:  Tsun Leung Chan; Yee Wai Chan; Judy W C Ho; Celine Chan; Annie S Y Chan; Emily Chan; Polly W Y Lam; Chun Wah Tse; Kam Cheong Lee; Chi Waii Lau; Elaine Gwi; Suet Yi Leung; Siu Tsan Yuen
Journal:  Am J Hum Genet       Date:  2004-03-23       Impact factor: 11.025

View more
  4 in total

1.  High risk of colorectal and endometrial cancer in Ashkenazi families with the MSH2 A636P founder mutation.

Authors:  Bhramar Mukherjee; Gad Rennert; Jaeil Ahn; Sara Dishon; Flavio Lejbkowicz; Hedy S Rennert; Stacey Shiovitz; Victor Moreno; Stephen B Gruber
Journal:  Gastroenterology       Date:  2011-03-16       Impact factor: 22.682

2.  Mutation spectrum in HNPCC in the Israeli population.

Authors:  Yael Goldberg; Rinnat M Porat; Inbal Kedar; Chen Shochat; Michal Sagi; Avital Eilat; Suzan Mendelson; Tamar Hamburger; Aviram Nissan; Ayala Hubert; Luna Kadouri; Eli Pikarski; Israela Lerer; Dvorah Abeliovich; Dani Bercovich; Tamar Peretz
Journal:  Fam Cancer       Date:  2008-04-04       Impact factor: 2.375

3.  Homozygosity of MSH2 c.1906G-->C germline mutation is associated with childhood colon cancer, astrocytoma and signs of Neurofibromatosis type I.

Authors:  Helen Toledano; Yael Goldberg; Inbal Kedar-Barnes; Hagit Baris; Rinnat M Porat; Chen Shochat; Dani Bercovich; Eli Pikarsky; Israela Lerer; Isaac Yaniv; Dvorah Abeliovich; Tamar Peretz
Journal:  Fam Cancer       Date:  2008-12-20       Impact factor: 2.375

4.  A novel MSH2 germline mutation in a Druze HNPCC family.

Authors:  Jamal Zidan; Renée C Niessen; Yael Laitman; Dennie Rozeveld; Robert M W Hofstra; Eitan Friedman
Journal:  Fam Cancer       Date:  2007-07-29       Impact factor: 2.375

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.